Evidence map›Paper›PMID 32029221›Full record

ArticleMolecular metabolism2020

Single-cell ATAC-Seq in human pancreatic islets and deep learning upscaling of rare cells reveals cell-specific type 2 diabetes regulatory signatures.

Vivek Rai, Daniel X Quang, Michael R Erdos, Darren A Cusanovich, Riza M Daza, Narisu Narisu, Luli S Zou, John P Didion, Yuanfang Guan, Jay Shendure and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
19.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 138 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Vivek RaiDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Daniel X QuangDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Michael R ErdosNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Darren A CusanovichDepartment of Genome Sciences, University of Washington, Seattle, WA, 98109, USA.
Riza M DazaDepartment of Genome Sciences, University of Washington, Seattle, WA, 98109, USA.
Narisu NarisuNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Luli S ZouNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
John P DidionNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Yuanfang GuanDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.
Jay ShendureDepartment of Genome Sciences, University of Washington, Seattle, WA, 98109, USA.
Stephen C J ParkerDepartment of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Human Genetics, University of Michigan, Ann Arbor, MI, 48109, USA. Electronic address: scjp@umich.edu.
Francis S CollinsNational Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA. Electronic address: collinsf@od.nih.gov.
National Institutes of Health · USUniversity of Michigan · USUniversity of Washington · US

Funding

Genetic analysis of type II diabetes in Finnish populationZIAHG000024 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI ERDOS, MICHAEL · 2009 to 2025
$38.2M
Regional Pilot And Feasibility Study Grants ProgramP30DK020572 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Mehboob A Hussain · 2013 to 2026
$24.3M
CARDIOVASCULAR RESEARCH TRAINING PROGRAMT32HL007828 · NHLBI · UNIVERSITY OF WASHINGTON · PI Francis Kim, Farid Moussavi-Harami · 1997 to 2026
$10.2M
Machine Learning for Drug Response PredictionR35GM133346 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yuanfang Guan · 2019 to 2026
$3.2M
Context-specific and combinatorial genetic regulatory grammars in diabetesR01DK117960 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Stephen CJ Parker · 2018 to 2026
$2.8M
Scalable and Translational Analysis Tools on the Cloud for Deep Integrative Omics DataU01HL137182 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZHOU, XIANG · 2017 to 2019
$1.6M
Intramural NIH HHS ZIA HG000024NHLBI NIH HHS T32 HL007828NHLBI NIH HHS U01 HL137182NIDDK NIH HHS P30 DK020572NIDDK NIH HHS R01 DK117960NIGMS NIH HHS R35 GM133346
6 · The paper itself

Abstract

objectiveType 2 diabetes (T2D) is a complex disease characterized by pancreatic islet dysfunction, insulin resistance, and disruption of blood glucose levels. Genome-wide association studies (GWAS) have identified > 400 independent signals that encode genetic predisposition. More than 90% of associated single-nucleotide polymorphisms (SNPs) localize to non-coding regions and are enriched in chromatin-defined islet enhancer elements, indicating a strong transcriptional regulatory component to disease susceptibility. Pancreatic islets are a mixture of cell types that express distinct hormonal programs, so each cell type may contribute differentially to the underlying regulatory processes that modulate T2D-associated transcriptional circuits. Existing chromatin profiling methods such as ATAC-seq and DNase-seq, applied to islets in bulk, produce aggregate profiles that mask important cellular and regulatory heterogeneity.

methodsWe present genome-wide single-cell chromatin accessibility profiles in >1,600 cells derived from a human pancreatic islet sample using single-cell combinatorial indexing ATAC-seq (sci-ATAC-seq). We also developed a deep learning model based on U-Net architecture to accurately predict open chromatin peak calls in rare cell populations.

resultsWe show that sci-ATAC-seq profiles allow us to deconvolve alpha, beta, and delta cell populations and identify cell-type-specific regulatory signatures underlying T2D. Particularly, T2D GWAS SNPs are significantly enriched in beta cell-specific and across cell-type shared islet open chromatin, but not in alpha or delta cell-specific open chromatin. We also demonstrate, using less abundant delta cells, that deep learning models can improve signal recovery and feature reconstruction of rarer cell populations. Finally, we use co-accessibility measures to nominate the cell-specific target genes at 104 non-coding T2D GWAS signals.

conclusionsCollectively, we identify the islet cell type of action across genetic signals of T2D predisposition and provide higher-resolution mechanistic insights into genetically encoded risk pathways.

Indexed as

Chromatin Immunoprecipitation SequencingDeep LearningSingle-Cell AnalysisDiabetes Mellitus, Type 2Gene Expression ProfilingHumansIslets of LangerhansPolymorphism, Single NucleotideChromatinDeep learningEpigenomicsIsletSingle cellType 2 diabetes

Identifiers

PMID32029221
PMCPMC6961712
OpenAlexW2996385620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.